Evaxion A/s revenue

Evaxion A/s's revenue was $7.5m in fiscal 2025, up 125.1% on the year before.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Evaxion A/s: revenue history, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	0	73	3,344	7,528
Growth on the year before	—	—	+>999%	+125.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Evaxion A/s	$7.5m	125.1%	—
Roivant Sciences Ltd.	$7.5m	-67.6%	-46.4%
Adagene Inc.	$7.7m	7332.8%	—
Tscan Therapeutics, Inc.	$7.1m	2.2%	-24.3%
Coya Therapeutics, Inc.	$8.0m	1793.8%	—
Aclaris Therapeutics, Inc.	$8.2m	-51.0%	-35.9%

Compare with peers

Head to head: EVAX vs ROIV ADAG vs EVAX EVAX vs TCRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Evaxion A/s's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Evaxion A/s.